Navigation Links
Nile Therapeutics to Present at Two Upcoming Investor Conferences
Date:11/3/2008

SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc., (Nasdaq: NLTX), announced today that Peter Strumph, Chief Executive Officer, will present at the following upcoming investor conferences:

-- Rodman & Renshaw 10th Annual Healthcare Conference at 2:25 p.m. ET in the Kennedy II room on Monday, November 10, 2008 at The Palace Hotel in New York, NY.

-- Lazard Capital Markets 5th Annual Healthcare Conference at 9:00 a.m. ET on Wednesday, November 19, 2008 in the La Maisonette I room at The St. Regis Hotel in New York, NY.

Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including interim data from Nile's Phase 2a study for its lead compound, CD-NP, a novel chimeric peptide for the treatment of heart failure.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
3. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
4. United Therapeutics Reports Third Quarter 2008 Financial Results
5. Arete Therapeutics Bolsters Management Team
6. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
7. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
8. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
9. Nektar Therapeutics to Webcast R&D Day on November 12th
10. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
11. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... China , today announced that its board of directors has ... the plan from March 27, 2017 to March 27, 2018. The amendment ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a China ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, ... elastic characteristics when deformed, which is identical to how the human discs work ... forces and return to its natural state along a hysteresis curve, exactly like ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseqâ„¢ ... developed with input from industry experts to ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. ... Used combined in one project, multi-biometric solutions ... ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):